The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2006 Release

November 21, 2006 Eisai Announces Establishment of New Pharmaceuticals Marketing Subsidiary in Portugal
November 20, 2006 Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP)
October 31, 2006 Eisai Launches New Rx-to-OTC Switch Product Higuard(R) for Allergy-related Rhinitis and Skin Problems
October 30, 2006 Notice Regarding Revision of the Annual Business Forecast and Year-end Dividend Forecast by Subsidiary
October 26, 2006 Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand
October 19, 2006 Sanko Junyaku, Eisai, and FUJIREBIO Sign Joint Research Agreement for Development of a New KL-6 Test Kit (supplementary diagnostic marker for interstitial pneumonia) compatible with LUMIPULSE(R) (automatic chemiluminescent enzyme immunoassay system)
October 19, 2006 Notice Regarding Revision of the Semiannual Business Forecast by Subsidiary
October 14, 2006 U.S. FDA Approves Aricept(R) For Treatment of Severe Alzheimer's Disease
October 9, 2006 Eisai Receives Decisions of Summary Judgment Motion in US Legal Action Over Aciphex(R) ANDA Filing
October 2, 2006 Eisai's research subsidiary “KAN Research Institute” launches research operations in The Kobe Medical Industry Development Project Site
September 27, 2006 Eisai's Lawsuit against three Japanese Generic drug manufacturers/distributors regarding the sales of Selbex(R) based on the Japanese Unfair Competition Prevention Law dismissed by Court
September 8, 2006 Eisai Acquires Four Oncology-Related Products from Ligand
August 30, 2006 Notice Concerning the Result of the Company's Own Share Acquisition through ToSTNet-2
August 29, 2006 Notice Concerning Acquisition of the Company's Own Shares through ToSTNet-2
August 4, 2006 Eisai Commences U.S. Legal Action over Aricept ODT(R) ANDA Filing
July 31, 2006 Eisai Starts Marketing Severe Chronic Pain Agent Prialt(R) in the UK and Germany
July 31, 2006 Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
July 31, 2006 Notice Concerning Acquisition of the Company's Own Shares
July 27, 2006 Co-development and Distribution Agreement on treatment for pancreatic exocrine insufficiency (SA-001) in Japan concluded
July 12, 2006 Eisai and Teva Mutually Agree To End Collaboration Agreement for Rasagiline
July 10, 2006 Notice on Stock Options (New Share Subscription Rights) Including the Amount Paid In Upon the Exercise of Stock Options
July 4, 2006 Pharmaceutical Marketing Subsidiary in Singapore Launches Operations
June 29, 2006 Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius
June 23, 2006 Notice on Allotment of Stock Options (New Share Subscription Rights)
May 19, 2006 Notice Concerning Dissolution of Subsidiary
May 16, 2006 Notice on Partial Amendments to the Articles of Incorporation
May 16, 2006 Notice on New Stock Issuance in the Form of Stock Options
May 16, 2006 Eisai Files Application with the MHRA for New Aricept(R) Indication: Severe Alzheimer's Disease
May 10, 2006 Eisai and Nitto Denko Sign a Joint Development Agreement on a Transdermal Patch Formulation of Aricept(R)
May 9, 2006 Eisai will initiate first clinical study for E2012, a potential new treatment for Alzheimer's Disease
April 21, 2006 Personal Information Documentation Loss Release
April 17, 2006 Dainippon Sumitomo Pharma and Eisai Signed Licensing Agreement for "Gasmotin(R)", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members
March 31, 2006 Asahi Kasei Pharma and Eisai sign sales promotion agreement for Eril(R) in China
March 30, 2006 Eisai and DNAVEC Sign an Agreement on Drug Discovery Research for Vaccine Therapy for Alzheimer's Disease
March 29, 2006 Notice of Shelf Registration for Stock Options
March 27, 2006 Eisai Applies for a New Indication of Non-Erosive Gastro-Esophageal Reflux Disease for Pariet(R) a Proton Pump Inhibitor, in Japan
March 16, 2006 Eisai Reports Results from Latest Donepezil Study in Vascular Dementia
February 28, 2006 Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
February 28, 2006 Announcement of the 5th Mid-term Strategic Plan
February 24, 2006 Notice Concerning the Split-off of Management Function of the R&D Division and Other Relevant Function of Eisai Co., Ltd.
February 14, 2006 FDA Accepts Eisai's sNDA Application for Aricept(R) In the Treatment of Severe Alzheimer's Disease
February 9, 2006 Eisai Agrees To Acquire Severe Chronic Pain Agent PrialtTM For Europe From Elan
February 2, 2006 Notice Concerning Revision of Year End Dividend Forecast For Fiscal Year Period (94th Company Fiscal Period) Ending March 2006
January 24, 2006 Eisai establishes a European strategic business hub in the U.K.
January 13, 2006 Legal Action taken against Generic Products of Eisai's Selbex(R) Capsule 50mg based on the Japanese Unfair Competition Prevention Law in the Japanese Market

Back to Top